Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05385783 · ClinicalTrials.gov registry record · Phase 1
A Study of a Psilocybin Analog (CYB003) in Healthy Participants With and Without Major Depressive Disorder
A Phase 1 study, sponsored by Cybin IRL Limited.
- Completed
- Registry status
- Phase 1
- Development phase
- 57
- Enrollment target
NCT05385783 is a Phase 1 study that has completed, run by Cybin IRL Limited. The registered enrollment target is 57 participants.
The verdict
NCT05385783, a Phase 1 study, has completed, sponsored by Cybin IRL Limited.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 57 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and tolerability of ascending oral doses of CYB003 in healthy participants with and without major depressive disorder (MDD).
Interventions
- DRUG Placebo
- BEHAVIORAL Psychotherapy
- DRUG CYB003
- BEHAVIORAL Psychological Support
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2022-08-02 |
| Est. Completion | 2024-01-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05385783
The ClinicalTrials.gov registry entry for NCT05385783 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cybin IRL Limited, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT05385783 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05385783 about?
NCT05385783 is a clinical study titled "A Study of a Psilocybin Analog (CYB003) in Healthy Participants With and Without Major Depressive Disorder". The purpose of this study is to determine the safety and tolerability of ascending oral doses of CYB003 in healthy participants with and without major depressive disorder (MDD).
What is the current status of trial NCT05385783?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 57 participants. The study started on 2022-08-02. Estimated completion is 2024-01-18.
What interventions are being tested in trial NCT05385783?
The interventions under investigation include: Placebo (DRUG), Psychotherapy (BEHAVIORAL), CYB003 (DRUG), Psychological Support (BEHAVIORAL).
Who is sponsoring clinical trial NCT05385783?
This trial is sponsored by Cybin IRL Limited, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.